Skip to main content
Caplight Logo









Inverna Therapeutics

Inverna Therapeutics

Private
OdenseHealthcare & Life Scienceshttps://www.invernatx.com/

Last Round

Grant

Oct 9, 2025

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Inverna Therapeutics is a biotechnology company that is a developer of a next-generation ribonucleic acid splicing modulation platform intended to transform patient outcomes in severe genetic diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Revenue Share, Government Contracts

AI Layer

Non-AI

Keywords

RNA splicing modulationoligonucleotide therapypseudo-exon activationantisense oligonucleotideASOsplice switchingHuntington's diseaseParkinson's diseaseRNA therapyneurodegenerative diseasedrug discovery platformgenetic diseaseallele-specific targetingLRRK2 targetpre-clinical biotech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Inverna Therapeutics Comparables

Compare Inverna Therapeutics with similar companies based on industry and business-model similarity.

Inverna Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Harness Therapeutics
79%
Vico
76%
Skyhawk Therapeutics
73%

Inverna Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantOct 9, 2025
SeedJan 7, 2025

Key People

Founding team and executive leadership

Poul Sørensen

CEO and Executive Chairman

Executive Team

Inverna Therapeutics Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 25, 2026

    Monthly visitors grew 509% MoM, from 157 to 956.

  • Apr 17, 2026

    Monthly visitors increased 139% MoM.

Inverna Therapeutics Filings

Explore SEC and related filing metadata, where available.

Inverna Therapeutics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Inverna Therapeutics's valuation, stock price, and market status.

Is Inverna Therapeutics a public or private company?

Inverna Therapeutics is a private company.

What is the current stock price of Inverna Therapeutics?

Inverna Therapeutics is a private company with no public stock price. No recent secondary market data is available.

How much is Inverna Therapeutics worth (valuation)?

Valuation information for Inverna Therapeutics is not publicly available.

Can I buy Inverna Therapeutics stock?

Inverna Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Inverna Therapeutics's last funding round?

Inverna Therapeutics's most recent funding round was Grant on October 9, 2025.

Who are the main investors in Inverna Therapeutics?

Key investors in Inverna Therapeutics include University of Southern Denmark, The Michael J. Fox Foundation for Parkinson's Research.

Will Inverna Therapeutics IPO soon?

No public IPO plans have been announced for Inverna Therapeutics.

How can I track Inverna Therapeutics secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Inverna Therapeutics's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersOdense
Employee Range3
Year Founded2024
Last FundingOct 9, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?